NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its quarterly earnings results on Thursday, February, 27th. The company reported ($1.77) EPS for the quarter, missing the Zacks' consensus estimate of ($1.14) by $0.63. View Apellis Pharmaceuticals' Earnings History.

10 brokerages have issued 12 month price targets for Apellis Pharmaceuticals' shares. Their forecasts range from $23.00 to $80.00. On average, they expect Apellis Pharmaceuticals' share price to reach $46.09 in the next year. This suggests a possible upside of 37.2% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

Media stories about APLS stock have trended extremely negative on Friday, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Apellis Pharmaceuticals.

Apellis Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,670,000 shares, an increase of 22.4% from the January 15th total of 5,450,000 shares. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 12.6% of the company's stock are short sold. View Apellis Pharmaceuticals' Current Options Chain.

Some companies that are related to Apellis Pharmaceuticals include Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), KemPharm (KMPH), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), ChemoCentryx (CCXI) and Exelixis (EXEL).

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (3.10%), State Street Corp (3.07%), Victory Capital Management Inc. (2.90%), FIL Ltd (1.86%), Barclays PLC (1.55%) and Jennison Associates LLC (1.48%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.

APLS stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Fiduciary Trust Co., Jane Street Group LLC, SG Americas Securities LLC, Candriam Luxembourg S.C.A., Pictet Asset Management Ltd., Baird Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois and Pascal Deschatelets. View Insider Buying and Selling for Apellis Pharmaceuticals.

APLS stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Victory Capital Management Inc., Farallon Capital Management LLC, Victory Capital Management Inc., FIL Ltd, FMR LLC and Bank of Montreal Can. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APLS stock can currently be purchased for approximately $33.60.

Apellis Pharmaceuticals has a market capitalization of $2.52 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]